CA2934024C - Kallikrein 7 inhibitors - Google Patents

Kallikrein 7 inhibitors Download PDF

Info

Publication number
CA2934024C
CA2934024C CA2934024A CA2934024A CA2934024C CA 2934024 C CA2934024 C CA 2934024C CA 2934024 A CA2934024 A CA 2934024A CA 2934024 A CA2934024 A CA 2934024A CA 2934024 C CA2934024 C CA 2934024C
Authority
CA
Canada
Prior art keywords
phenyl
acetate
ethyl
oxo
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934024A
Other languages
English (en)
French (fr)
Other versions
CA2934024A1 (en
Inventor
Marcel Linschoten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixera Pharma AB
Original Assignee
Sixera Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma AB filed Critical Sixera Pharma AB
Publication of CA2934024A1 publication Critical patent/CA2934024A1/en
Application granted granted Critical
Publication of CA2934024C publication Critical patent/CA2934024C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2934024A 2014-01-23 2015-01-22 Kallikrein 7 inhibitors Active CA2934024C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430004 2014-01-23
SE1430004-0 2014-01-23
PCT/SE2015/050060 WO2015112079A1 (en) 2014-01-23 2015-01-22 New kallikrein 7 inhibitors

Publications (2)

Publication Number Publication Date
CA2934024A1 CA2934024A1 (en) 2015-07-30
CA2934024C true CA2934024C (en) 2022-08-23

Family

ID=53681745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934024A Active CA2934024C (en) 2014-01-23 2015-01-22 Kallikrein 7 inhibitors

Country Status (18)

Country Link
US (1) US9744148B2 (https=)
EP (1) EP3097084B1 (https=)
JP (2) JP6552010B2 (https=)
CN (1) CN106132940B (https=)
AU (1) AU2015209759B2 (https=)
CA (1) CA2934024C (https=)
CY (1) CY1123707T1 (https=)
DK (1) DK3097084T3 (https=)
ES (1) ES2834851T3 (https=)
HR (1) HRP20201915T1 (https=)
HU (1) HUE052990T2 (https=)
LT (1) LT3097084T (https=)
PL (1) PL3097084T3 (https=)
PT (1) PT3097084T (https=)
RS (1) RS61142B1 (https=)
SI (1) SI3097084T1 (https=)
SM (1) SMT202000653T1 (https=)
WO (1) WO2015112079A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3097084B1 (en) * 2014-01-23 2020-09-30 Sixera Pharma AB New kallikrein 7 inhibitors
EP3305781A1 (en) * 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6)
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514355A1 (fr) * 1981-10-14 1983-04-15 Fabre Sa Pierre Derives de biphenyl alcoyl carboxylates, leur procede de preparation et leur utilisation comme medicaments
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
SI1631295T1 (sl) 2003-06-06 2010-06-30 Arexis Ab Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
US8486863B2 (en) * 2006-11-23 2013-07-16 Vib Vzw Activators of lateral root formation
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
PT2183273T (pt) 2007-08-17 2017-05-22 Novartis Ag Depsipéptidos cíclicos
WO2009024528A1 (en) * 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2545916A1 (en) 2011-07-15 2013-01-16 Universite Pierre Et Marie Curie - Paris 6 Use of coumarin derivatives for the preparation of drugs for treating skin diseases
EP3097084B1 (en) * 2014-01-23 2020-09-30 Sixera Pharma AB New kallikrein 7 inhibitors

Also Published As

Publication number Publication date
EP3097084B1 (en) 2020-09-30
JP6552010B2 (ja) 2019-07-31
CA2934024A1 (en) 2015-07-30
CN106132940A (zh) 2016-11-16
LT3097084T (lt) 2020-12-28
SI3097084T1 (sl) 2021-01-29
AU2015209759B2 (en) 2018-11-29
CN106132940B (zh) 2019-04-23
CY1123707T1 (el) 2022-03-24
EP3097084A1 (en) 2016-11-30
JP2019163296A (ja) 2019-09-26
US20170000753A1 (en) 2017-01-05
AU2015209759A1 (en) 2016-07-07
EP3097084A4 (en) 2017-10-04
PT3097084T (pt) 2020-12-09
HUE052990T2 (hu) 2021-05-28
PL3097084T3 (pl) 2021-02-22
WO2015112079A1 (en) 2015-07-30
SMT202000653T1 (it) 2021-01-05
DK3097084T3 (da) 2020-12-21
JP6932386B2 (ja) 2021-09-08
ES2834851T3 (es) 2021-06-18
HRP20201915T1 (hr) 2021-01-22
RS61142B1 (sr) 2020-12-31
US9744148B2 (en) 2017-08-29
JP2017505299A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
CA2934024C (en) Kallikrein 7 inhibitors
JP6858286B2 (ja) ライソゾーム蓄積症を治療するためのシクロデキストリン
Swarnakar et al. Matrix metalloproteinases in health and disease: regulation by melatonin
AU2015209761B2 (en) Benzoxazinone derivatives for treatment of skin diseases
Sathya et al. BACE1 in Alzheimer's disease
JP6185549B2 (ja) 新規のｔｒｐｖ１抑制ペプチド及びこれを含有する皮膚老化防止またはしわ改善用組成物
WO2014059306A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
JP2017505299A5 (https=)
McCormick et al. The biology of zinc transport in mammary epithelial cells: implications for mammary gland development, lactation, and involution
EA017735B1 (ru) Циклические депсипептиды
WO2007097980A9 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
JPWO2009063885A1 (ja) マイタケ抽出物及びこれを含むヒアルロン酸（ヒアルロナン）産生を促進するための組成物
KR100937263B1 (ko) 카텝신 ｇ 저해제를 함유하는 피부노화 방지용 피부외용제조성물 및 항노화용 물질을 스크리닝하는 방법
HK1229791A1 (en) New kallikrein 7 inhibitors
JP7433625B2 (ja) Ｍｍｐ発現抑制剤
Stura Dipartimento di Farmacia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191119

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250722

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106